Page 225«..1020..224225226227..230240..»

Category Archives: Stem Cells

Afriye Amerson on cord blood promotion to expectant mothers – at World Cord Blood Congress 2012 – Video

Posted: December 21, 2012 at 5:46 am


Afriye Amerson on cord blood promotion to expectant mothers - at World Cord Blood Congress 2012
Dr. Afriye Amerson, OB/GYN at the Amerson Women #39;s Health Center, spoke at the World Cord Blood Congress 2012 on the topic, #39;Engaging OB/GYNs to increase cord blood promotion to expectant mothers. #39; World Cord Blood Congress is where private and public cord blood banks, pharma and biotechs, academia and government come to debate advances in cord blood banking and therapeutics. For more information, go to http://www.terrapinn.com/cordblood. Or, check out our blog at blogs.terrapinn.com/total-biopharma for up to date information on the stem cells, RM and cord blood banking and therapeutics sectors.From:biopharmachannelViews:0 0ratingsTime:23:35More inScience Technology

Read the original:
Afriye Amerson on cord blood promotion to expectant mothers - at World Cord Blood Congress 2012 - Video

Posted in Stem Cells | Comments Off on Afriye Amerson on cord blood promotion to expectant mothers – at World Cord Blood Congress 2012 – Video

Dana Callow of Boston Millennia Partners on VCs and cord blood – at World Cord Blood Congress 2012 – Video

Posted: December 21, 2012 at 5:46 am


Dana Callow of Boston Millennia Partners on VCs and cord blood - at World Cord Blood Congress 2012
Dana Callow Jr., Managing General Partner at Boston Millennia Partners, spoke at the World Cord Blood Congress 2012 on the topic, #39;What the venture world looks for when investing in cord blood. #39; World Cord Blood Congress is where private and public cord blood banks, pharma and biotechs, academia and government come to debate advances in cord blood banking and therapeutics. For more information, go to http://www.terrapinn.com/cordblood. Or, check out our blog at blogs.terrapinn.com/total-biopharma for up to date information on the stem cells, RM and cord blood banking and therapeutics sectors.From:biopharmachannelViews:0 0ratingsTime:23:33More inScience Technology

More:
Dana Callow of Boston Millennia Partners on VCs and cord blood - at World Cord Blood Congress 2012 - Video

Posted in Stem Cells | Comments Off on Dana Callow of Boston Millennia Partners on VCs and cord blood – at World Cord Blood Congress 2012 – Video

“Neural Stem Cells for Severe Spinal Cord Injury” – Dr. Mark Tuszynski – Video

Posted: December 21, 2012 at 5:45 am


"Neural Stem Cells for Severe Spinal Cord Injury" - Dr. Mark Tuszynski
Dr. Tuszynski discusses the findings reported in the journal "Cell" that showed extensive growth of axons in spinal cord injury using grafts of early stage neural stem cells.From:unite2fightparalysisViews:0 0ratingsTime:33:47More inNonprofits Activism

View post:
"Neural Stem Cells for Severe Spinal Cord Injury" - Dr. Mark Tuszynski - Video

Posted in Stem Cells | Comments Off on “Neural Stem Cells for Severe Spinal Cord Injury” – Dr. Mark Tuszynski – Video

Stem Cells Therapy by Dr BS Rajput – Video

Posted: December 19, 2012 at 10:45 pm


Stem Cells Therapy by Dr BS Rajput
Dr.BS Rajput Sr.Consultant Orthopedic Stem Cell Transplant Surgeon mob-+91 9820850187,9811763787 drrajput09820850187@gmail.com http://www.drrajput.inFrom:ZandZMediaViews:1 2ratingsTime:05:00More inScience Technology

Read the original:
Stem Cells Therapy by Dr BS Rajput - Video

Posted in Stem Cells | Comments Off on Stem Cells Therapy by Dr BS Rajput – Video

Exploring the Straw Man Argument Against IOM Reforms at California Stem Cell Agency

Posted: December 19, 2012 at 10:38 pm

Constitutional objections to some of
the Institute of Medicine's sweeping recommendations for changes at
the $3 billion California stem cell agency amount to little more than
a straw man, at least based on a legal memo produced earlier by the
agency.

The legal objections to structural reforms at the
agency were initially advanced in 2009 when the stem cell agency was
fighting an unwelcome analysis of its activities by the state's good
government agency, the Little Hoover Commission. The objections were
voiced again at a meeting earlier this month by some governing board
members, particularly Sherry Lansing, who is also chairwoman of the
University of California regents. Her comments came within minutes of
the start of the Institute of Medicine's (IOM) presentation to the
board.
She said directors' hands “are tied”
because of requirements in Proposition 71, the ballot initiative that
created the stem cell agency, which is formally known as the
California Institute for Regenerative Medicine(CIRM). While Lansing
did not elaborate, some of the initiative is written into the state
constitution, which can only be amended by a vote of the people.
However, Proposition 71 can also be amended by a 70 percent vote of
each house of the Legislature and the signature of the governor,
which is no small task to achieve.
The 2009 legal memo (see the full text
below) dealt with the recommendations of the Little Hoover
Commission, some of which were cited and echoed by the IOM. The legal
memo contended that the legislature was barred from making major
changes in the structure of the stem cell agency governing board
because the changes supposedly would not “enhance the ability of
the (agency) to further the purposes of the grant and loan programs.”
The argument was that only the people could make “non-enhancing”
changes. The vague “enhancement” requirement was written into
Proposition 71 by its authors, one of whom is James Harrison, the
outside counsel to the board, who was also the lead author on the
2009 memo. Harrison is revisiting the supposed constitutional issues in the wake of the IOM study.
However, the objections cited in his earlier memo are dubious and easily overcome. The meaning of “enhance” is
so vague as to permit wide interpretations. Certainly, removing
public suspicion about conflicts of interest would seem to help move
the agency forward. Straightening out the muddled management
structure of the agency, with its overlapping responsibilities for
the chairman and president, would certainly seem to enhance the
functioning of the agency. Assuring that the governing board has the
full ability to exercise strong oversight over the conduct of the
agency would certainly seem to be an enhancement and long overdue.
At least that is what the most
prestigious body of its sort says. The Institute of Medicine studied
the agency for 17 months under a $700,000 contract with CIRM. The
IOM's charge was to evaluate the performance of the agency and make
recommendations for improvements. The IOM recommendations echoed
findings not only of the Little Hoover Commission, but some in two
earlier studies also funded by the agency.
For CIRM directors now to reject the
IOM findings and turn away would be to indicate that their earlier
admiration and respect for the IOM was something of a sham or, more
likely, now inconvenient.
As for removing ambiguity about what
does or does not enhance the agency's mission, the 29-member board
could simply adopt a resolution declaring that all the IOM
recommendations would enhance the CIRM mission.
One of major obstacles to acting on the
earlier recommendations for changes was Robert Klein, the first
chairman of the agency board. Klein, an attorney and real estate investment
banker, also directed the writing of Proposition 71 and wrote
portions of it himself. He would often make numerical code citations
to the initiative during agency board meetings.
Klein is now gone from the board,
leaving in 2011 at the end of his term. He was replaced by Jonathan
Thomas
, a Los Angeles bond financier, who has ushered in a new and
different era at the stem cell agency. Some might say a more
reasonable era. He says he and governing board
take the IOM study seriously. 
The report is scheduled for discussion
Jan. 23 at a public workshop at the Claremont Hotel in Berkeley, Ca.,
the day before the regular board meeting. .
The IOM's recommendations have won theeditorial endorsement of all the California newspapers that have so
far written about them. The newspapers believe that the proposals
would indeed enhance the agency's mission and are, in fact, necessary
if the agency is to survive beyond 2017, when the money for new
grants runs out.
Directors of the stem cell agency are
currently mulling the future of their efforts. If they are to be
successful in raising additional hundreds of millions of dollars –
be they private or public – the directors must confront the
findings of the IOM in a forthright manner. And they must move to
dispel the cloud that now hangs over the stem cell agency.
(Editor's note: The full text of the
2009 legal memo can be found below. Also below is another related
legal memo from Americans for Cures, a stem cell lobbying group
sponsored by Robert Klein at the same time he was chairman of the
stem cell agency. Despite the language on the Americans for Cures
memo, it is a public record. It became a public document when Klein
submitted it to the Little Hoover Commission.) 

Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/8TDUJVXl3rw/exploring-straw-man-argument-against.html

Posted in Stem Cells, Stem Cell Therapy | Comments Off on Exploring the Straw Man Argument Against IOM Reforms at California Stem Cell Agency

Balloting Begins on Stem Cell Person of the Year

Posted: December 19, 2012 at 2:38 am

The nominations are in. Voting has
begun, with about 1,000 ballots cast so far. But only one vote truly
counts. That belongs to Paul Knoepfler, who is running the The Stem
Cell Person of the Year
contest and will pony up $1,000 of his
hard-earned cash to honor the winner.
On Monday, Knoepfler announced 16 finalists out of 30 nominees. They range from scientists to patients
to advocates. Voting began instantly and will continue until Dec. 31
at 11:59 p.m. Votes will count for something, but Knoepfler makes it clear that they are only advisory. He makes the decision.
This is Knoepfler's first year at the
contest. The UC Davis stem cell researcher, patient advocate and
blogger wants to recognize someone who made a difference and took
some risks in doing so.
You can find the entire list of
candidates on Knoepfler's blog, but we wanted to note that they have
a father and son competing against each other – Don Reed and his
son, Roman. (Could be tense around the holiday tables in the
Reeds' households.) Also on the list is Jeanne Loring of Scripps,
whose nominator said engages the wider community with great
effectiveness. I once heard Loring say that every stem cell
researcher should have a spiel that could be delivered in five
minutes in a taxi and that would not only explain stem cell research,
but persuade the cab driver of its virtues.
All of the nominees have much to
recommend them. Knoepfler will be chewing his fingernails before this
is all over.  

Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/_Zshc3lQops/balloting-begins-on-stem-cell-person-of.html

Posted in Stem Cells, Stem Cell Therapy | Comments Off on Balloting Begins on Stem Cell Person of the Year

“Study of Human Neural Stem Cells in Thoracic Spinal Cord Injury” – Stephen Huhn, MD – Video

Posted: December 18, 2012 at 1:42 pm


"Study of Human Neural Stem Cells in Thoracic Spinal Cord Injury" - Stephen Huhn, MD
Dr. Huhn, who is Vice President, Head of the CNS Program at Stem Cells, Inc., provides an update on the company #39;s clinical trial.From:unite2fightparalysisViews:0 0ratingsTime:23:03More inNonprofits Activism

Go here to see the original:
"Study of Human Neural Stem Cells in Thoracic Spinal Cord Injury" - Stephen Huhn, MD - Video

Posted in Stem Cells | Comments Off on “Study of Human Neural Stem Cells in Thoracic Spinal Cord Injury” – Stephen Huhn, MD – Video

California Editorial Unamity: Stem Cell Agency Needs Revamp

Posted: December 18, 2012 at 12:40 pm

With the addition of another editorial
this week, reaction among California newspapers so far has been
unanimous that the $3 billion California stem cell agency should heed
the sweeping recommendations of the prestigious Institute of
Medicine.

The Riverside Press-Enterprise added its voice yesterday, declaring,

“Good intentions do not justify poor
practice.”

Like others, the newspaper said that
the agency “needs to revamp its governance structure to avoid
potential conflicts of interest and boost public confidence in the
agency.”
The Riverside paper focused on the conflicts of interest at the organization, which has seen about
90 percent of its funding go to institutions with ties to directors, but also supported other recommendations, including elimination of the dual executive arrangement at the research effort. 
The editorial said,

“An agency spending Californians’
money has no business being cavalier about good government practice
and ethical safeguards — no matter how promising the potential
therapies might be. The stem-cell institute is not a private fiefdom,
but a taxpayer-supported undertaking. Yet many on the stem-cell
institute’s board objected this month to the report’s
recommendations.

“The agency also said that Prop. 71’s
provisions mean that enacting many of the proposed fixes would
require either a supermajority vote of the Legislature or another
ballot measure. That prospect should warn Californians about the
dangers of voting for complex, costly, politically driven initiatives
that have little to do with fundamental state duties.

“Still, the stem-cell agency cannot
just sit on these recommendations without damaging its credibility.
The search for medical breakthroughs does not justify ignoring vital
safeguards for spending taxpayer dollars.”

For a look at other editorials, see here and here.Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/70xi8-waM7k/california-editorial-unamity-stem-cell.html

Posted in Stem Cells, Stem Cell Therapy | Comments Off on California Editorial Unamity: Stem Cell Agency Needs Revamp

Southern California Newspaper Tackles Stem Cell Agency and UC Irvine Grants

Posted: December 16, 2012 at 3:43 pm

The Orange County Register today zeroed
in on the $3 billion California stem cell agency and its relationship
to the local University of California campus in the wake of sweeping
recommendations for changes at the eight-year-old agency.

The article by Melody Petersen was
headlined “Ties to stem cell board lucrative.”
Petersen began her article with story of the $20 million award to StemCells, Inc., earlier this year and
the firm's partnership with Frank LaFerla of UC Irvine, which is located in Orange County.
The award was rejected twice by
reviewers at the stem cell agency but the governing board of the
agency (CIRM) approved it on a 7-5 vote in September following
lobbying on behalf of the company by the board's former chairman,
Robert Klein, and others.
Petersen said the award was not the first time that questions have been raised about stem cell agency grants. She said that the 17-month study by the prestigious Institute of
Medicine (IOM)
and some of its findings, particularly those dealing
with conflicts of interest, echoed criticisms that have been raised for years.
She wrote,

“Repeated independent reviews of the
agency, including one by the (IOM) released this month, have found
that its board is rife with conflicts of interest. In fact, of the
$1.7 billion that the agency has awarded so far, about 90 percent has
gone to research institutions with ties to people sitting on the
board, according to an analysis by David Jensen at the California
Stem Cell Report
, which closely follows the agency's operations.

While the agency has yet to produce a
cure, Petersen said,

“What's clear already is that the
money has transformed stem cell research in California and poured
hundreds of millions of dollars into the state's universities,
including UC Irvine.”

She noted that the CIRM governing board
is dominated by members from the UC system, including two professors
at UC Irvine.
Peterson continued,

“Before Proposition 71 (the measure
that created the agency) passed, UC Irvine had less than ten stem
cell scientists, who received about $1.5 million in funding each
year. Now, after receiving $100 million in grants from the state
agency, the university has sixty scientists working to advance stem
cell research and teaching. It touts itself as one of the top stem
cell research centers in the world. In 2010, it opened an $80 million
four-story stem cell research center with the agency picking up $27
million of the cost.

“As UC Irvine has won increasing
amounts of taxpayer money, its two professors who sit on the agency's
board have risen in status on campus.

Susan Bryant
UC Irvine photo

“Professor Susan Bryant, an expert in
regenerative medicine, was dean of the School of Biological Sciences
when she was named to the agency's board in 2004. She was then
promoted to vice-chancellor of research. In July, she was named the
university's interim executive vice-chancellor and provost, its
second most powerful administrator.

“When Professor Oswald Steward, a
stem cell scientist, joined the agency's board in 2004, he was
director of UCI's Reeve-Irvine Research Center for Spinal Injury.
Since then, the scientists working in his center have received
millions of dollars in grants from the agency. In May, the university
rewarded Steward with an additional title: senior associate dean of
research for the School of Medicine.”

“The two professors are prohibited
from receiving any agency funds for their own scientific work. But so
much money has been funneled into the stem cell field in California
that it can be difficult to show their continued scientific efforts
are not somehow benefiting. For example, Bryant co-authored a
scientific article in 2009 with nine other scientists about the
genetics of salamanders, which can regenerate limbs. In the report,
the group recognized the state agency for partially funding their
work. Bryant said that the money was received by another scientist in
the group who was not employed by UC Irvine. She said the state
agency has never given a grant for research involving salamanders. 'I
have never-ever benefited from CIRM funding,' Bryant said using the
agency's acronym.

Os Steward
UC Irvine photo

“Steward said he stopped his stem
cell research when he joined the board in 2004. His board position,
he said, 'has prevented me from taking on lines of research I
otherwise would do.'

Tom Vasich, a campus spokesperson,
said Bryant and Stewart's positions on the agency's board played no
part in their promotions and success at the school.”

Petersen additionally reported that
Steward and Bryant are not allowed to vote on grants to UC Irvine.
Petersen pointed out that the
University of California has 16 members on the 29-member board. One
of those is the chairwoman of the UC Regents, Sherry Lansing.
Petersen also noted that three of the UC officials, including
Steward, hold seats on the board as patient advocates.

Petersen is a recent addition to the
Register's staff, joining it in November as an investigative
reporter. She worked as a business reporter for the New York Times and authored  "Our Daily Meds," a book about the pharmaceutical industry. She shared in the top award in newspaper financial journalism when she was at the San Jose Mercury News.  

Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/41IPNEUfHpo/southern-california-newspaper-tackles.html

Posted in Stem Cells, Stem Cell Therapy | Comments Off on Southern California Newspaper Tackles Stem Cell Agency and UC Irvine Grants

Two More Editorials: The California Stem Cell Agency Should Heed IOM Recommendations for Reform

Posted: December 16, 2012 at 8:01 am

Two other major California newspapers
today said the $3 billion California stem cell agency needs to “clean
up its act” if it wants to be successful in continuing its efforts
at turning stem cells into cures.

The editorials appeared in the Los Angeles
Times
, the state's largest circulation newspaper at more than
700,000, and the San Jose Mercury News in California's Silicon Valley.
The Mercury News has a reported circulation of nearly 600,000,
although that figure includes other Bay Area newspaper owned by the
same chain.
Both editorials focused on the 17-month evaluation of the agency by the prestigious Institute of Medicine (IOM) as did earlier editorials in The Sacramento Bee and the San Francisco Chronicle. The IOM recommended sweeping reforms at the agency that would alter its structure and target conflicts of interest. 

“The $700,000 spent on the
study...will be wasted if the institute's oversight board fails to
heed the (IOM) committee's
criticisms,
 which echo the findings of the Little Hoover
Commission
and other groups over the years.”

The editorial continued,

“The 29-member board is made up
almost entirely of representatives of advocacy groups and research
institutions that have a direct interest in how the money is spent.”

The Times cited the California Stem
Cell Report'
s calculations that about 90 percent of the $1.7 billion awarded by CIRM has gone to institutions linked to current and former members of its governing board. 
The Times noted an award to a Northern California firm that has stirred some criticism. The editorial said,

“The board also overrode the advice
of its scientific advisors — twice on a single application when it
considered a grant for a well-connected company, StemCells Inc. based
in Newark, Calif. The board granted the company $20 million after Robert Klein, the driving force behind the passage of Proposition 71,
which created and funded the agency in 2004, and its former head,
lobbied so intensively for the company that one board member
described it as 'arm-twisting.'"

The Times concluded,

“The agency has used more than half
of its funding and one day will almost certainly want to ask
taxpayers for more. It should remember that voters will look for
evidence of public accountability as well as respected research.”

The San Jose paper sounded a similar
note about the agency. Its editorial said,

“(I)f it wants to survive...it
should heed the Institute of Medicine's advice to eliminate conflicts
of interest on its board -- and do it before awarding the remaining
$1.2 billion of the $3 billion voters approved for stem cell
research.”

But the paper said the stem cell agency
should not be provided any more state funding.

“Long-term funding was never the
intent when Proposition 71 passed in 2004. It was supposed to
kick-start research at a time when federal funding was blocked and to
establish California as a major player in the rapidly advancing
medical field. 

“The agency could continue to bring
value to the state as an advocate and funder of research, but only if
it can attract private donors, partners and investors. For that to
happen, it will need a board that passes the ethics test, with more
independent experts and industry executives free of conflicts. 

“At the outset, stem cell advocates
took immense pride in structuring the agency to keep it relatively
free of legislative interference despite the use of public money.
Politicians kept their hands off, which was good. But the agency
created its own inappropriate influences in the way it constituted
its board. Now it needs to clean up its act.“

Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/hjDmQPb6wDs/two-more-editorials-california-stem.html

Posted in Stem Cells, Stem Cell Therapy | Comments Off on Two More Editorials: The California Stem Cell Agency Should Heed IOM Recommendations for Reform

Page 225«..1020..224225226227..230240..»